WO2001055317A3 - Acides nucleiques, proteines et anticorps - Google Patents

Acides nucleiques, proteines et anticorps Download PDF

Info

Publication number
WO2001055317A3
WO2001055317A3 PCT/US2001/001329 US0101329W WO0155317A3 WO 2001055317 A3 WO2001055317 A3 WO 2001055317A3 US 0101329 W US0101329 W US 0101329W WO 0155317 A3 WO0155317 A3 WO 0155317A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
testicular
testes
polynucleotides
methods
Prior art date
Application number
PCT/US2001/001329
Other languages
English (en)
Other versions
WO2001055317A8 (fr
WO2001055317A2 (fr
Inventor
Craig A Rosen
Steven C Barash
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven C Barash
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven C Barash, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to EP01922229A priority Critical patent/EP1252337A2/fr
Priority to AU2001249053A priority patent/AU2001249053A1/en
Priority to US09/908,711 priority patent/US20020045230A1/en
Publication of WO2001055317A2 publication Critical patent/WO2001055317A2/fr
Publication of WO2001055317A3 publication Critical patent/WO2001055317A3/fr
Publication of WO2001055317A8 publication Critical patent/WO2001055317A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne de nouveaux polynucléotides liés aux testicules, et les polypeptides codés par ces polynucléotides connus ici sous la dénomination collective de 'antigènes testiculaires', et l'utilisation d'antigènes testiculaires de ce type pour détecter des troubles liés aux testicules, en particulier la présence du cancer des testicules et de métastases de cancer des testicules. Plus spécifiquement, l'invention concerne des molécules d'acide nucléique isolées associées aux testicules, codant pour de nouveaux polypeptides associés aux testicules. Cette invention concerne également des polypeptides et anticorps testiculaires qui se lient à ces polypeptides ; des vecteurs, des cellules hôtes, des procédés de recombinaison et de synthèse permettant de produire des polynucléotides et/ou polypeptides humains associés aux testicules ; des procédés diagnostiques et thérapeutiques utiles pour le diagnostic, le traitement, la prévention et/ou la prévision de troubles liés aux testicules, y compris le cancer des testicules, et des procédés de traitement de troubles de ce type ; des procédés de criblage permettant d'identifier des agonistes et des antagonistes de polynucléotides et polypeptides de l'invention ; des procédés et/ou des compositions permettant d'inhiber la production et la fonctionnalité de polypeptides de la présente invention.
PCT/US2001/001329 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps WO2001055317A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01922229A EP1252337A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
AU2001249053A AU2001249053A1 (en) 2000-01-31 2001-01-17 Nucleic acids, proteins, and antibodies
US09/908,711 US20020045230A1 (en) 2000-08-14 2001-07-20 Nucleic acids, proteins, and antibodies

Applications Claiming Priority (235)

Application Number Priority Date Filing Date Title
US17906500P 2000-01-31 2000-01-31
US60/179,065 2000-01-31
US18062800P 2000-02-04 2000-02-04
US60/180,628 2000-02-04
US18466400P 2000-02-24 2000-02-24
US60/184,664 2000-02-24
US18635000P 2000-03-02 2000-03-02
US60/186,350 2000-03-02
US18987400P 2000-03-16 2000-03-16
US60/189,874 2000-03-16
US19007600P 2000-03-17 2000-03-17
US60/190,076 2000-03-17
US19812300P 2000-04-18 2000-04-18
US60/198,123 2000-04-18
US20551500P 2000-05-19 2000-05-19
US60/205,515 2000-05-19
US20946700P 2000-06-07 2000-06-07
US60/209,467 2000-06-07
US21488600P 2000-06-28 2000-06-28
US60/214,886 2000-06-28
US21513500P 2000-06-30 2000-06-30
US60/215,135 2000-06-30
US21688000P 2000-07-07 2000-07-07
US21664700P 2000-07-07 2000-07-07
US60/216,880 2000-07-07
US60/216,647 2000-07-07
US21748700P 2000-07-11 2000-07-11
US21749600P 2000-07-11 2000-07-11
US60/217,496 2000-07-11
US60/217,487 2000-07-11
US21829000P 2000-07-14 2000-07-14
US60/218,290 2000-07-14
US22096300P 2000-07-26 2000-07-26
US22096400P 2000-07-26 2000-07-26
US60/220,963 2000-07-26
US60/220,964 2000-07-26
US22526600P 2000-08-14 2000-08-14
US22575900P 2000-08-14 2000-08-14
US22527000P 2000-08-14 2000-08-14
US22521300P 2000-08-14 2000-08-14
US22575800P 2000-08-14 2000-08-14
US22526800P 2000-08-14 2000-08-14
US22521400P 2000-08-14 2000-08-14
US22544700P 2000-08-14 2000-08-14
US22526700P 2000-08-14 2000-08-14
US22451800P 2000-08-14 2000-08-14
US22451900P 2000-08-14 2000-08-14
US22575700P 2000-08-14 2000-08-14
US60/225,759 2000-08-14
US60/224,518 2000-08-14
US60/225,266 2000-08-14
US60/225,447 2000-08-14
US60/224,519 2000-08-14
US60/225,213 2000-08-14
US60/225,758 2000-08-14
US60/225,268 2000-08-14
US60/225,757 2000-08-14
US60/225,267 2000-08-14
US60/225,214 2000-08-14
US60/225,270 2000-08-14
US22627900P 2000-08-18 2000-08-18
US60/226,279 2000-08-18
US22668100P 2000-08-22 2000-08-22
US22718200P 2000-08-22 2000-08-22
US22686800P 2000-08-22 2000-08-22
US60/227,182 2000-08-22
US60/226,868 2000-08-22
US60/226,681 2000-08-22
US22700900P 2000-08-23 2000-08-23
US60/227,009 2000-08-23
US22892400P 2000-08-30 2000-08-30
US60/228,924 2000-08-30
US22934500P 2000-09-01 2000-09-01
US22928700P 2000-09-01 2000-09-01
US22934300P 2000-09-01 2000-09-01
US22934400P 2000-09-01 2000-09-01
US60/229,344 2000-09-01
US60/229,345 2000-09-01
US60/229,343 2000-09-01
US60/229,287 2000-09-01
US22950900P 2000-09-05 2000-09-05
US22951300P 2000-09-05 2000-09-05
US60/229,509 2000-09-05
US60/229,513 2000-09-05
US23043700P 2000-09-06 2000-09-06
US23043800P 2000-09-06 2000-09-06
US60/230,437 2000-09-06
US60/230,438 2000-09-06
US23141400P 2000-09-08 2000-09-08
US23208100P 2000-09-08 2000-09-08
US23124400P 2000-09-08 2000-09-08
US23208000P 2000-09-08 2000-09-08
US23124200P 2000-09-08 2000-09-08
US23124300P 2000-09-08 2000-09-08
US23141300P 2000-09-08 2000-09-08
US60/231,243 2000-09-08
US60/231,414 2000-09-08
US60/232,080 2000-09-08
US60/231,242 2000-09-08
US60/231,244 2000-09-08
US60/232,081 2000-09-08
US60/231,413 2000-09-08
US23196800P 2000-09-12 2000-09-12
US60/231,968 2000-09-12
US23239900P 2000-09-14 2000-09-14
US23239700P 2000-09-14 2000-09-14
US23240000P 2000-09-14 2000-09-14
US23240100P 2000-09-14 2000-09-14
US23306500P 2000-09-14 2000-09-14
US23239800P 2000-09-14 2000-09-14
US23306400P 2000-09-14 2000-09-14
US23306300P 2000-09-14 2000-09-14
US60/233,064 2000-09-14
US60/232,400 2000-09-14
US60/232,401 2000-09-14
US60/232,397 2000-09-14
US60/232,398 2000-09-14
US60/233,065 2000-09-14
US60/233,063 2000-09-14
US60/232,399 2000-09-14
US23422300P 2000-09-21 2000-09-21
US23427400P 2000-09-21 2000-09-21
US60/234,223 2000-09-21
US60/234,274 2000-09-21
US23499700P 2000-09-25 2000-09-25
US23499800P 2000-09-25 2000-09-25
US60/234,997 2000-09-25
US60/234,998 2000-09-25
US23548400P 2000-09-26 2000-09-26
US60/235,484 2000-09-26
US23583600P 2000-09-27 2000-09-27
US23583400P 2000-09-27 2000-09-27
US60/235,834 2000-09-27
US60/235,836 2000-09-27
US23636700P 2000-09-29 2000-09-29
US23632700P 2000-09-29 2000-09-29
US23636900P 2000-09-29 2000-09-29
US23637000P 2000-09-29 2000-09-29
US23636800P 2000-09-29 2000-09-29
US60/236,370 2000-09-29
US60/236,367 2000-09-29
US60/236,369 2000-09-29
US60/236,327 2000-09-29
US60/236,368 2000-09-29
US23703900P 2000-10-02 2000-10-02
US23704000P 2000-10-02 2000-10-02
US23703700P 2000-10-02 2000-10-02
US23703800P 2000-10-02 2000-10-02
US23680200P 2000-10-02 2000-10-02
US60/237,037 2000-10-02
US60/237,039 2000-10-02
US60/236,802 2000-10-02
US60/237,038 2000-10-02
US60/237,040 2000-10-02
US23993500P 2000-10-13 2000-10-13
US23993700P 2000-10-13 2000-10-13
US60/239,937 2000-10-13
US60/239,935 2000-10-13
US24178700P 2000-10-20 2000-10-20
US24178600P 2000-10-20 2000-10-20
US24178500P 2000-10-20 2000-10-20
US24180900P 2000-10-20 2000-10-20
US24122100P 2000-10-20 2000-10-20
US24182600P 2000-10-20 2000-10-20
US24180800P 2000-10-20 2000-10-20
US24096000P 2000-10-20 2000-10-20
US60/241,787 2000-10-20
US60/241,808 2000-10-20
US60/241,809 2000-10-20
US60/241,221 2000-10-20
US60/241,786 2000-10-20
US60/241,785 2000-10-20
US60/240,960 2000-10-20
US60/241,826 2000-10-20
US24461700P 2000-11-01 2000-11-01
US60/244,617 2000-11-01
US24647800P 2000-11-08 2000-11-08
US24661300P 2000-11-08 2000-11-08
US24647500P 2000-11-08 2000-11-08
US24652500P 2000-11-08 2000-11-08
US24652600P 2000-11-08 2000-11-08
US24652800P 2000-11-08 2000-11-08
US24647400P 2000-11-08 2000-11-08
US24660900P 2000-11-08 2000-11-08
US24647600P 2000-11-08 2000-11-08
US24647700P 2000-11-08 2000-11-08
US24653200P 2000-11-08 2000-11-08
US60/246,611 2000-11-08
US60/246,477 2000-11-08
US60/246,528 2000-11-08
US60/246,478 2000-11-08
US60/246,527 2000-11-08
US60/246,524 2000-11-08
US60/246,610 2000-11-08
US60/246,609 2000-11-08
US60/246,526 2000-11-08
US60/246,523 2000-11-08
US60/246,525 2000-11-08
US60/246,613 2000-11-08
US60/246,532 2000-11-08
US60/246,474 2000-11-08
US60/246,476 2000-11-08
US60/246,475 2000-11-08
US60/249,245 2000-11-17
US60/249,211 2000-11-17
US60/249,208 2000-11-17
US60/249,244 2000-11-17
US60/249,209 2000-11-17
US60/249,214 2000-11-17
US60/249,264 2000-11-17
US60/249,213 2000-11-17
US60/249,217 2000-11-17
US60/249,216 2000-11-17
US60/249,207 2000-11-17
US60/249,215 2000-11-17
US60/249,299 2000-11-17
US60/249,297 2000-11-17
US60/249,300 2000-11-17
US60/249,265 2000-11-17
US60/249,212 2000-11-17
US60/249,218 2000-11-17
US60/249,210 2000-11-17
US60/250,391 2000-12-01
US60/250,160 2000-12-01
US60/251,030 2000-12-05
US60/251,988 2000-12-05
US60/256,719 2000-12-05
US60/251,479 2000-12-06
US60/251,869 2000-12-08
US60/251,989 2000-12-08
US60/251,990 2000-12-08
US60/251,868 2000-12-08
US60/251,856 2000-12-08
US60/254,097 2000-12-11
US60/259,678 2001-01-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/908,711 Continuation-In-Part US20020045230A1 (en) 2000-08-14 2001-07-20 Nucleic acids, proteins, and antibodies

Publications (3)

Publication Number Publication Date
WO2001055317A2 WO2001055317A2 (fr) 2001-08-02
WO2001055317A3 true WO2001055317A3 (fr) 2002-01-03
WO2001055317A8 WO2001055317A8 (fr) 2002-05-16

Family

ID=27587113

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2001/001307 WO2001054472A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001329 WO2001055317A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001307 WO2001054472A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Country Status (2)

Country Link
CA (1) CA2393616A1 (fr)
WO (2) WO2001054472A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1686134A3 (fr) * 1999-12-01 2006-08-09 Genentech, Inc. Polypeptides transmembranaires et secrétés et les acides nucléiques codant ceux-ci
AU4592601A (en) * 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
US20040005664A1 (en) 2000-04-25 2004-01-08 Millennium Pharmaceuticals, Inc. Novel 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 molecules and uses therefor
WO2001085921A2 (fr) * 2000-05-12 2001-11-15 Merck Patent Gmbh Nouvelle serine-threonine kinase-4
EP2168980A1 (fr) * 2000-06-23 2010-03-31 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse
WO2002010217A2 (fr) 2000-08-02 2002-02-07 The Johns Hopkins University Profils d'expression de cellules endotheliales
US6962799B2 (en) * 2000-08-21 2005-11-08 Incyte Corporation Microtubule-associated proteins and tubulins
AU2001284757A1 (en) * 2000-09-01 2002-03-22 Millennium Pharmaceuticals, Inc. 26199, 33530, 33949, 47148, 50226, and 58764, human transferase family members and uses therefor
US6692748B2 (en) 2000-12-07 2004-02-17 Zymogenetics, Inc. Adipocyte complement related protein zacrp3x2 and nucleic acids encoding zacrp3x2
EP1409536A2 (fr) * 2001-02-12 2004-04-21 Curagen Corporation Proteines, polynucleotides codant pour lesdites proteines et methodes d'utilisation desdites proteines
AU2002346978A1 (en) * 2001-10-09 2003-04-22 Bayer Healthcare Ag Human gtpase involved in chronic obstructive pulmonary disease (copd)
CA2466415C (fr) * 2001-11-09 2020-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1.beta., un nouvel homologue du pgc-1 et leurs utilisations
EP1446487A1 (fr) * 2001-11-13 2004-08-18 Sugen, Inc. Phosphatases proteiques de mammiferes
EP2275544A3 (fr) 2002-06-06 2011-03-30 Oncotherapy Science, Inc. Gènes et polypeptides en rapport avec les cancers du colon chez l'homme
FR2840925B1 (fr) 2002-06-18 2005-04-01 Riber Chambre d'evaporation de materiaux sous vide a pompage differentiel
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
WO2007068784A1 (fr) 2005-12-14 2007-06-21 Licentia Ltd Nouveau facteur neurotrophique et utilisations de celui-ci
ATE479754T1 (de) 2003-03-19 2010-09-15 Biogen Idec Inc Nogo rezeptor bindendes protein
DE10344799A1 (de) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
RS52593B (en) 2004-06-24 2013-04-30 Biogen Idec Ma Inc. TREATMENT OF THE CONDITIONS CONCERNING DEMYELINIZATION
EP2394661A1 (fr) 2005-07-08 2011-12-14 Biogen Idec MA Inc. Anticorps Sp35 et utilisations associées
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CA2997870A1 (fr) 2008-07-09 2010-01-14 Biogen Ma Inc. Compositions renfermant des anticorps au lingo ou des fragments associes
CA2830065A1 (fr) 2011-03-16 2012-09-20 Amgen Inc. Inhibiteurs puissants et selectifs de nav1.3 et nav1.7
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
JP6530742B2 (ja) 2013-03-15 2019-06-12 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 腸内病原体の免疫応答を強化する組成物及び方法
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035259A1 (fr) * 1997-12-30 1999-07-15 Nps Allelix Corp. Identification des recepteurs des lysolipides impliques dans la reponse inflammatoire

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631584A4 (fr) * 1991-02-28 1998-07-01 Dana Farber Cancer Inst Inc Diagnostic et therapie du cancer.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035259A1 (fr) * 1997-12-30 1999-07-15 Nps Allelix Corp. Identification des recepteurs des lysolipides impliques dans la reponse inflammatoire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 1 January 1999 (1999-01-01), Database accession no. AF034780 *
MACLENNAN ET AL.: "Cloning and characterization of a putative G-protein coupled receptor potentially involved in development", MOL. CELL. NEUROSCI., vol. 5, no. 3, 1994, pages 201 - 209, XP002946839 *

Also Published As

Publication number Publication date
WO2001054472A3 (fr) 2002-01-31
WO2001055317A8 (fr) 2002-05-16
WO2001054472A2 (fr) 2001-08-02
WO2001054472A8 (fr) 2001-09-07
WO2001055317A2 (fr) 2001-08-02
CA2393616A1 (fr) 2001-08-02

Similar Documents

Publication Publication Date Title
WO2001055316A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055317A3 (fr) Acides nucleiques, proteines et anticorps
WO2002000677A8 (fr) Acides nucleiques, proteines et anticorps
WO2001059063A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055168A8 (fr) Acides nucleiques, proteines, et anticorps
WO2001055300A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055313A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055167A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055329A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055162A8 (fr) Acides nucleiques, proteines et anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 31/2001 UNDER "PUBLISHED", DELETE "SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU."

CFP Corrected version of a pamphlet front page
WWE Wipo information: entry into national phase

Ref document number: 2393616

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001922229

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001922229

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001922229

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)